间歇性甲状旁腺激素治疗对人类骨重塑与骨建模的细胞效应:以骨组织形态计量学为中心的范围综述
该范围综述汇总并重新解读骨组织形态计量学结合骨转换标志物的研究,探讨间歇性甲状旁腺激素治疗在骨内的细胞效应。骨质疏松症治疗前6个月破骨细胞和成骨细胞活性均增加,骨形成在7-18个月后回归基线;甲状旁腺功能减退症治疗72-120个月使骨形成正常化至匹配健康对照水平。基于骨建模的骨形成并非甲状旁腺激素诱导骨形成的主要方式,破骨细胞启动的骨重塑类骨形成为主要模式。
要点
- 骨质疏松症中,间歇性甲状旁腺激素治疗前6个月破骨细胞和成骨细胞活性均增加,7-18个月后骨形成回归基线。
- 甲状旁腺功能减退症治疗72-120个月使骨形成正常化至匹配健康对照水平,破骨细胞情况 largely 未研究。
- 基于骨建模的骨形成并非甲状旁腺激素诱导骨形成的主要贡献者,破骨细胞启动的骨重塑类骨形成为主要模式。
核心结论
- 基于骨转换标志物与骨组织形态计量学的结合,作者建议在骨质疏松症中,单个破骨细胞的活性在治疗前18个月内增加。
- 在甲状旁腺功能减退症中,治疗长达72-120个月增加骨形成并使其正常化至匹配健康对照水平,而破骨细胞 largely 未研究。
- 与早期观点相反,基于骨建模的骨形成并非甲状旁腺激素诱导骨形成的主要贡献者,破骨细胞启动的骨形成如基于骨重塑的骨形成(RBF)和溢出性基于骨重塑的骨形成(oRBF)是骨形成的主要模式。
研究设计与样本
- 范围综述,汇总并重新解读使用骨组织形态计量学并辅以骨转换标志物的研究,以探讨间歇性甲状旁腺激素治疗在骨内的细胞效应并揭示知识空白。
主要发现
- 骨质疏松症中,间歇性甲状旁腺激素治疗前6个月内破骨细胞和成骨细胞活性均增加。
- 骨质疏松症中,前6个月成骨细胞活化增加骨形成,此后在治疗7-18个月后骨形成回归基线。
- 基于治疗24个月后可获得的研究,更多破骨细胞分布于骨表面,但单个破骨细胞可能活性降低,同时成骨细胞骨形成似乎重新激活。
- 甲状旁腺功能减退症中,治疗长达72-120个月增加骨形成并使其正常化至匹配健康对照水平,而破骨细胞 largely 未研究。
- 骨质疏松症和甲状旁腺功能减退症中骨形成表面的增加可能部分通过 rejuvenating 疾病期间积累的停滞侵蚀表面实现。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出需要进一步研究先前破骨细胞抑制性抗骨吸收治疗的可能影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Intermittent PTH treatment has been used as both an osteoanabolic treatment in osteoporosis and a hormone replacement in hypoparathyroidism for many years. This scoping review compiles and reinterprets studies using histomorphometry supported by bone turnover markers to investigate the elusive cellular effect of intermittent PTH treatment locally within the bone, while illuminating knowledge gaps. Intermittent PTH increases both osteoclast and osteoblast activity within the first 6 months of treatment. Based on the combination of systemic bone turnover markers and histomorphometry we suggest that in osteoporosis, the activity of the individual osteoclast increases within the first 18 months of treatment. During the initial 6 months, osteoblast activation increases bone formation, whereafter bone formation returns to baseline after 7-18 months of treatment. Based on the studies available after 24 months of treatment, more osteoclasts populate the bone surfaces, but the individual osteoclast may potentially be less active. At the same time, osteoblastic bone formation appears to be reactivated. In hypoparathyroidism, treatment up to 72-120 months increases bone formation and normalizes it to a level of matched healthy controls, while the osteoclast remains largely uninvestigated. The increase in bone forming surfaces in both osteoporosis and hypoparathyroidism may partly be achieved by rejuvenating arrested eroded surfaces accumulated during disease. Contrary to early beliefs, modeling-based bone formation (MBF) is not a major contributor to PTH-induced bone formation. Rather osteoclast-initiated bone formations such as remodeling-based bone formation (RBF) and overflow remodeling-based bone formation (oRBF) are the predominate modes of bone formation, underlining a need for further investigations into possible effects of previous osteoclast-inhibiting anti-resorptive treatment.
引用
- Thomsen LK, van Dijk Christiansen P, Andreasen CM, et al. The cellular effect of intermittent PTH treatment on bone remodeling and modeling in humans-a histomorphometry centered scoping review. Osteoporos Int. 2025. PMID: 40924119. doi:10.1007/s00198-025-07612-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。